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ABSTRACT OF THESIS 
 
In Vivo Evolution of a Trans-Splicing Group I Intron Ribozyme 
 
by 
 
Ishani Behera 
 
Master of Science in Chemistry 
 
University of California San Diego, 2018 
 
Professor Ulrich Muller, Chair  
 
The Tetrahymena group I intron was one of the two first catalytic RNAs (ribozymes) to 
be discovered. Group I introns are sequences that can exist between exons in pre-mRNAs, that 
are able to self-splice and remove themselves when forming mature mRNAs in the absence of the 
spliceosome. The Tetrahymena cis-splicing ribozyme was engineered to accept substrate RNAs 
in trans. The designed trans-splicing ribozyme was termed the “spliceozyme”. The spliceozyme 
could in principle be used in therapeutic applications. However, there are two hurdles to 
overcome; the delivery of the ribozyme into cells and its efficiency once delivered. The focus of 
		 x 
this study is to improve the efficiency of the trans-splicing ribozyme in cells by evolving the 
ribozyme in E. coli.  In a previous study, an evolution system in cells was developed for the 
spliceozyme which was used to generate a clone, W11, that increased product formation. 
However, this evolution used high ribozyme expression levels and focused on a single splice site. 
To improve the efficiency and sequence generality, the spliceozyme was evolved at low 
expression levels at two different splice sites with different flanking sequences. The results of the 
spliceozyme evolution in bacterial cells showed that specific mutations are able to improve 
spliceozyme efficiency in bacterial cells. This suggests that further analysis, and perhaps further 
evolution experiments, could generate spliceozymes with improved efficiency on a broad range 
of substrate sequences.  
		 1 
Introduction 
 
The cis-splicing group I intron from Tetrahymena thermophila is one of the two first 
known catalytic RNAs (ribozymes) [1] [2]. Group I introns are sequences that can exist between 
exons in pre-mRNAs, that are able to self-splice and remove themselves when forming mRNAs 
in the absence of the spliceosome [1]. Group I introns use two consecutive trans-phosporylation 
reactions to self-splice [3]. With a Mg2+ cofactor, an exogenous guanosine initiates splicing 
through a nucleophilic attack by its free 3' hydroxyl group on the phosphate of the 5' splice site. 
The 5' splice site is based on recognition of a conserved wobble pair between the terminal U of 
the 5' exon and a conserved G within the intron’s internal guide sequence (Figure 1) [4]. A 
conformational change, aided by the P10 helix, brings the 3' splice site to the active site which 
aligns the 5' and 3' exons.  The free 3' hydroxyl group at the 5' splice site then attacks the 3' 
splice site, ligating the exons and releasing the intron. The 3' splice site is recognized by a 
conserved terminal G which is selected through hydrogen bonding and stacking interactions in 
the same site into which the endogenous G binds in the first step of the reaction cascade [5].  
Group I introns from genera Tetrahymena, Twort, and Azoarcus, have been well 
characterized both biochemically and structurally with five high-resolution crystal structures [6] 
[7] [8] [9]. Although these ribozymes differ in their peripheral regions, the core structure 
including the active site is conserved. The active site contains the bound guanosine (either the 
exogenous G or the 3'-terminal G), which completes a base triple, sandwiched by three other 
base triples, and a metal.  The Tetrahymena Group I intron provides the most detailed 
biochemical characterization [10]. The Tetrahymena ribozyme is robust with regard to different 
sequence contexts in the peripheral areas and is active in vitro, in bacteria, and in eukaryotes 
		 2 
including yeast, mouse, and human cells. The group I introns from Pneumocystis carinii [11], 
Candida albicans [12], Didymium and Fuligo [13], show similar potential but the well-studied 
Azoarcus ribozyme has very specific secondary structure requirements that make it less robust 
[14]. Therefore, most trans-splicing ribozyme studies focus on the Tetrahymena ribozyme which 
can be designed in different ways.  
 
Variants of the cis-splicing group I introns have been engineered to splice a substrate in 
trans. The first type of a trans-splicing ribozyme was designed based on the Tetrahymena Group 
I intron [15]. It could replace the 5' end of a substrate with the 3' end of the trans-splicing 
ribozyme. The trans-splicing ribozyme contacts the substrate by forming a P1 helix which docks 
into the active site allowing splicing at the 5' splice site. The free 3' hydroxyl group at the 5' 
Figure 1. Secondary structure of the Tetrahymena group I intron ribozyme [4]. In all subsequent 
figures, the P4-P6 domain will be shoes to the right of the rest of the ribozyme for easier 
visualization of the secondary structures at the catalytic site. 
		 3 
splice site is now free to attack the 3' end of the ribozyme resulting in the 5' portion of the 
substrate RNA and the 3' exon of the designed trans-splicing ribozyme [15] [16]. If a substrate 
RNA carries a mutation in its 3' portion, this trans-splicing ribozyme variant could be used to 
replace the 3' portion with a the wild-type sequence repairing the RNA.  
In contrast to the designed trans-splicing at the 5' splice site, a Pneumocystis carinii 
ribozyme variant splices at the 3' splice site and replaces the substrate 5' end with the ribozymes’ 
5' exon [17]. The ribozyme recognizes the 3' splice site of the substrate by forming the P10 and 
P9.0 duplexes. This variant can then splice at the substrate 3' splice site, and replace the 
substrates 5' portion with the 5' exon of the ribozyme construct in the P1 duplex leading to the 
replacement of the substrates 5' portion. If there is a mutation in the 5' portion of an RNA, this 
variant could be used to replace it with the wild type sequence.    
When both the 5' splice recognition and 3' splice recognition principles are combined in 
one ribozyme, it is possible to excise or insert a nucleotide in a substrate sequence. Variants 
based on the Pneumocystis carinii ribozyme have been engineered that trans-splice by using the 
P1 duplex as 5' splice recognition and the P9.0 and P10 duplexes as 3' splice recognition leading 
to the excision of internal sequences or an insertion in the internal sequence of an RNA [11]. The 
excision of longer fragments, up to 28 internal nucleotides of a substrate RNA has been shown in 
vitro [18] [19]. The efficiency of sequences longer than a single nucleotide is low in cells. [20]. 
The trans-splicing Pneumocystis carinii ribozyme could be used to remove insertion mutations 
or other frame-shift mutations in RNA. The insertion of short oligomeric sequences allows the 
insertion of modified RNAs into a target sequence in vitro for research purposes [21]. Thiol-
modifications or isotopically labelled oligomers could be inserted for biochemical or NMR 
analysis.  
		 4 
When a different principle is used for the recognition of the 3' splice site, a Tetrahymena 
group I intron variant is able to excise a 100-nt-long intron from pre-mRNAs both in vitro and in 
bacterial cells [22]. This variant uses the P9.0 and P9.2 duplexes for recognition of the 3' splice 
site; the 5' splice site is still recognized with the P1 duplex (Figure 2). The P9.2 helix is formed 
in trans between the 3' terminus of the ribozyme and the target sequence of the substrate. The 
minimal length of both the trans P9.2 and P1 helix is about 6-7 base pairs. The two trans-
phosphorylation reactions lead to the excision of the RNA segment between the 3' and 5' splice 
sites and the ligation of the upstream and downstream segments. These ribozymes are termed 
“spliceozymes” as they behave similarly to the spliceosome. 
 
Any uridine nucleotide in the substrate can be a possible target site for trans-splicing 
ribozymes due to the necessity of a G•U wobble pair. In order to predict efficient splice sites for 
the spliceozyme computationally, the binding free energies were calculated by summing 
computed energies of unfolding the target site, unfolding of the ribozyme 5' terminus, and the 
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Figure 2. Secondary structure of 5’ and 3’ trans-splicing ribozyme or spliceozyme. The 
spliceozyme (black) base pairs with the pre-mRNA (red) and intron (blue) by forming the P1, P9.2, 
and P9 duplexes. (A) Before the splicing reaction, the pre-mRNA contains the 5’ exon (red), an 
intron (blue), and the 3’ exon (red). The 5’ splice site is indicated by a filled triangle. The 3’ splice 
site is indicated with an open triangle. (B) After the splicing reaction the 5’ and 3’ exons are joined 
together (red) while the intron (blue) is excised. [22]
		 5 
binding of the target site and ribozyme 5' terminus [23]. The trans-splicing efficiency of 18 
different splice sites were tested on a chloramphenicol acetyl transferase (CAT) mRNA. The 
results correlated very well with the free energy predictions, and additionally identified a new 
splice site in position 258 of the CAT gene, which turned out to be more efficient than any other 
splice site on CAT mRNA. The second-most active splice site was splice site 448, at nucleotide 
position 448 of the CAT gene.   
To develop improved trans-splicing variants, an evolution system was designed in which 
the population generated and accumulated mutations that increase activity over multiple rounds 
of mutagenesis, selection, and amplification (Figure 3) [24] [25]. A Tetrahymena ribozyme 
variant was used to repair a CAT mRNA that was inactivated by a frameshift mutation in its’ 3' 
portion. Ribozyme variants that were able to correctly replace the 3' portion would lead to E. coli 
growth on medium containing chloramphenicol. This Tetrahymena ribozyme variant was 
subjected to 21 rounds of evolution. The most efficient variant that was tested after the 21 rounds 
had four clustered mutations in the P6b loop. These mutations generated an accessible (C)5 
homopentamer sequence which recruited the Rho transcription factor. These mutations did not 
increase trans-splicing efficiency, but increased the translation of the spliced mRNA. This 
showed that an evolving population in vivo can interact with cellular components to benefit its 
evolutionary interest. Using a similar evolution system, the spliceozyme was improved through 
10 rounds of evolution to generate a clone with improved splicing efficiency using a single splice 
site [26]. An intron was inserted into splice site 258 of CAT mRNA, the most efficient splice 
site, in order to inactivate it. The spliceozyme would have to remove this insertion thereby 
ligating the CAT mRNA together in order for E. coli to grow on medium containing 
chloramphenicol. The most efficient clone out of those that survived 10 rounds of evolution, 
		 6 
contained 10 mutations that increased product formation by reducing side product formation, 
reducing activity at the 5' splice site, and increasing activity at the 3' splice site. 
 
 Research aims to improve trans-splicing ribozymes not only from a biochemical 
perspective but for their ability to be used therapeutically. Trans-splicing ribozymes could be 
used therapeutically in two different ways. The first use for Group I intron ribozymes is to repair 
a disease-causing mutated mRNA by replacing the mutation portion of mRNA with the corrected 
sequence [15]. With current variants, the 3¢ terminal end or the 5' terminal end can be replaced 
[17]. If there is an insertion, this can also be removed through the use of a trans-splicing 
Transform
into E. coli
Isolate ribozyme gene 
by restriction digest, and
purify on agarose gel
Plate 3-10 million cells 
on selection medium
Chloramphenicol
Mutagenic PCR
pUC19
Spliceozyme
CAT pre-mRNA
Intron
Wash plates, 
isolate 
plasmids
Figure 3. Evolution of spliceozymes in bacterial cells. (A) A library plasmid is generated by cloning two 
expression cassettes into a pUC19-based vector (grey). The expression of chloramphenicol acetyl transferase 
(CAT) pre-mRNA (red) is driven by a constitutive promoter. The mRNA is inactivated by an intron (blue). 
Spliceozyme (black) expression is driven by an IPTG-inducible promoter. The substrate binding sites on the 
spliceozyme are designed to recognize the two splice sites of CAT pre-mRNA and remove the intron. (B)
After transformation of the library plasmid into E. coli and induction with IPTG, the bacterial library is 
plated on LB medium containing chloramphenicol. This allows only those bacterial cells to form colonies 
that contain spliceozymes able to remove the intron from CAT pre-mRNA. (C) The colonies are washed off 
the plates, and their plasmids isolated. (D) The spliceozyme genes are amplified from the isolated plasmids 
by PCR, and the PCR products separated from the plasmids by agarose gel electrophoresis. (E) The PCR 
products are used as templates for mutagenic PCR. This library of spliceozyme genes is cloned into a fresh 
library plasmid and subjected to additional evolution rounds.
Figure 2
A B
C
D
E
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ribozyme [11]. Second, they can be used to selectively kill disease causing cells by replacing a 
portion of an RNA with a ‘suicide gene’ such as diphtheria toxin A or herpes simplex virus 
thymidine kinase (HSV-tk) [27][28][29]. This will cause apoptosis or lead to the cell death. 
Cancer cells can be killed by group I introns in this manner [28]. A trans-splicing ribozyme can 
be used to target sites on RNAs that are highly expressed in cancer cells and splice a ‘suicide 
gene’ into those sites. The suicide gene can encode for diphtheria toxin A, a cytotoxic peptide, or 
a termination sequence, triggering cell death of the cancer cell. A trans-splicing ribozyme, 
currently in clinical trials, targets hTERT RNA, a highly expressed RNA in cancer cells [29]. 
The ribozyme can splice in a suicide gene that encodes for herpes simplex virus thymidine 
kinase(HSV-tk) which converts the prodrug ganciclovir to a highly genotoxic phosphorylated 
ganciclovir which acts as a chain terminator of DNA synthesis. This causes selective induced 
cell death only in dividing cells such as those found in tumors.  
Many other diseases can potentially be treated by trans-splicing ribozymes that occur due 
to mutations that cause alternative splicing. Some known alternative splicing disease include: 
familial dysautonoma, frontotemporal labor dementias, amyotrophic lateral sclerosis, 
Hutchinson-Gilford progeria syndrome, Medium-chain acyl-coA dehydrogenase (MCAD) 
deficiency, myotonic dystrophy, Prader-Willi Syndrome, Spinal muscular atrophy, b- 
thalassemia, and Tauopathies, which are caused by mutations at the 5' splice site, point mutations 
in regulatory sequences, exon skipping, or short repeat elements [30].  
In the future, the spliceozyme could be used to target mRNAs that have a retained intron 
from the alternative splicing process. In an analysis of 96,822 alternative splicing events using 23 
eukaryotic genomes, 12,337 (12.37%) were intron retention events [31].  For instance, an intron 
retention in the CACNA1H gene can lead to childhood absence epilepsy (CAE) and other 
		 8 
idiopathic generalize epilepsies. CAE occurs in children 4-10 years and can have ongoing effect 
into adulthood [32]. Children have absence seizures (4 to 20 seconds long) sometimes in the 
hundreds per days which can cause severe impairment of consciousness. CACNA1H regularly 
encodes for Cav3.2, a T-type member in the voltage-dependent calcium channel complex that 
helps mediate the influx of calcium ions into the cell upon membrane polarization.  A common 
mutation in the CACNA1H gene is the retention of intron 23 which is 60 amino acids long 
(about 180 nucleotides) which can cause bursting behavior in neurons. The spliceozyme could be 
used to target this 180-nucleotide long sequence and excise the remainder of intron 23 from the 
CACNA1H gene. Another possible target for the spliceozyme could be SPINK5 (serine protease 
inhibitor Kazal-type 5), which when mutated, can lead to Netherton syndrome [33]. Netherton 
syndrome is a severe skin disease in children and young adults that causes skin inflammation, 
universal itch, severe dehydration, stunted growth, reddish skin, and increases susceptibility to 
infections and allergies. A c.283-12T>A mutation in intron 4 causes retention of the last 10 
nucleotides of intron 4. A c.1820+53G>A in intron 19 and c.891C>T in exon 11 cause the 
retention of the first 54 nucleotides of intron 19. Any of these retentions cause a loss of function 
of SPINK5 leading to Netherton syndrome.  The spliceozyme could be used therapeutically to 
excise either or both partial introns. 
For the use of spliceozymes as tools in therapy, efficient delivery methods need to be 
developed. Currently, various delivery systems including adeno-virus vectors [34], enveloped 
protein nanocages [35], and modified Salmonella [36] are being developed but improvements to 
minimize toxicity, off-target effects, immune responses, and increase delivery to target tissues 
are necessary. Current adeno-virus vectors may be a possible delivery system for the 
spliceozymes. Additionally, the use of spliceozymes in therapy is limited by the efficiency, 
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accuracy and off-target effects, and general utility in cells. Efficiency is based on how much 
substrate becomes product. Spliceozyme accuracy depends on binding to the correct splice site 
and splicing at the correct base. A minimization of off-target effects is important to confirm that 
the spliceozyme targets the correct mRNA and not does not splice any others. This study aims to 
improve the use of spliceozymes for use in therapy by lowering the expression level to improve 
splicing efficiency and by switching splice sites to improve its specificity and general utility in E. 
coli cells.  
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Results 
 
A previously developed spliceozyme [22] is able to remove a 100-nucleotide intron from 
the pre-mRNA of chloramphenicol acetyl transferase (CAT) in E. coli cells, with an efficiency 
high enough to support the growth of E. coli bacteria on medium containing chloramphenicol. 
This spliceozyme was evolved in E. coli cells to mediate growth at increased chloramphenicol 
concentrations (Figure 3) resulting in a spliceozyme variant termed W11, containing 10 
mutations from the parent sequence [26]. This spliceozyme W11 is more efficient than the parent 
spliceozyme because it has an increased activity at the 3' splice site, and a decreased activity at 
the 5' splice site. This resulted in a 6-fold decrease of side products relative to products at shorter 
time points (20 min and 30 min), and a 2-fold increase in product formation at longer time points 
(60 minutes). These previous results showed that evolution in E. coli cells is able to fine-tune the 
sequence and reaction characteristics of the spliceozyme for improved performance. 
To be useful in a clinical setting, the existing spliceozyme would have to be improved in two 
ways. First, the expression level of spliceozymes in the previous studies was about 10,000 
molecules per cell, which would be too high for a clinical setting [25]. Second, the evolutionary 
optimization of the spliceozyme was done on a single splice site of CAT mRNA (splice site 258) 
with a single intron sequence [26]. This splice site is the most efficient in CAT mRNA for trans-
splicing group I intron ribozymes, and most splice sites show much lower splicing efficiency 
[23]. In a clinical setting, the spliceozymes should be expressed at low intracellular 
concentrations, and work with similar efficiency at many different target sites. To identify 
spliceozymes that work efficiently at low expression levels, and less sequence dependence, we 
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evolved spliceozymes in E. coli cells at low expression levels, and with a swapping of splice 
sites and intron sequences over the course of the evolution.  
 
Evolution conditions that would adjust the spliceozymes for low expression levels would be 
spliceozyme expression levels as low as possible - but high enough to mediate growth of E. coli 
cells on medium containing chloramphenicol. In addition, the spliceozyme promoter used in the 
evolution needed to be inducible by IPTG such that the bacteria could be grown in the absence of 
spliceozyme expression on medium containing ampicillin. This would only select for the 
presence of the plasmid and not for or against specific spliceozyme variants. To develop such 
promoter sequences, we started by testing five different IPTG-inducible lac promoters [38] to 
medicate weak, spliceozyme-mediated growth. The promoter closest to the desirable behavior 
A87 (weak LacI promoter variant; Cox et al. (2007)) -35 box -10 box
TACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGATTTTCTGATACTTCGTG...
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGATTNNNNGATACTGTGTGG
A87 3.1a (selected from the A87b library)
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACANNNNATGTGGATTTTCTGATACTGTGTGG
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATANNNNTTGACAATCAATGTGGATTTTCTGATACTGTGTGG
A87b (library based on A87) 
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGATTCACAGATACTGTGTGG
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGTACCACAGATACTGTGTGG
A87.1 (clone A87.3.1a with KpnI site)
A87.2 (library based on A87.1)
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGTACCACANNNNCTGTGTGG
GAATTGGTACAACGTCGTGTTAGCTGCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGTACCACAAAGCCTGTGTGG
A87.2.5  ("promoter 5", selected from A87.2 library) 
Figure 4. Development of the spliceozyme expression "promoter 5" that was used for the evolution. (A) the 
starting construct A87, which showed the weakest expression of five LacI promoter constructs in a previous 
publication (CoxElowitz07). (B) Library A87b, based on promoter A87, which was used to identify weaker 
promoters than A87. The red upstream was attached to facilitate cloning. The red downstream sequence was 
taken from our previous spliceozyme expression constructs. (C) Clone A87 3.1a resulted from one round of 
selection, and screening for weak growth, from the A87b library. (D) Clone 87.1 is identical to 87 3.1a, with 
exception that a KpnI cloning site was inserted into the promoter for easier cloning. This promoter mediated 
slightly stronger growth than A87 3.1a. (E) Library based on clone A87.2, with an NNNN sequence replacing the 
first four nucleotides of the -10 box. After one selection round, four clones were identified with weak growth. The 
spliceozyme expression in these clones was measured by RT-qPCR, showing an ~300-fold reduction compared to 
A87.1. (F) Clone A87.2.5 ("promoter 5") was chosen for the evolution due to its low expression level and the 
ability to mediate bacterial growth on LBcam. 
(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
Figure 4
		 12 
was promoter A87 (Figure 4A). In four steps, we converted promoter A87 to "promoter 5", 
which showed low expression level and the ability to mediate bacterial growth on LBcam 
medium.  
In the first step, four positions in promoter A87 were randomized, in three different 
positions (Figure 2B). This library was screened for weak growth on LB medium containing 
chloramphenicol (4 mg/mL). This identified clone A87 3.1a (Figure 4C). In the second step, the 
restriction site KpnI was inserted into promoter A87 3.1a to allow easier cloning. This resulted in 
promoter A87.1 (Figure 4D), which mediated slightly stronger bacterial growth on medium 
containing chloramphenicol that A87 3.1a. From promoter A87.1, a library was generated by 
randomizing the first four nucleotides of the -10 promoter box (Figure 4E). From this library, 
four clones were identified as showing the desired, very weak growth on medium containing 
chloramphenicol. Promoter A87.2.5 ("promoter 5"; Figure 4F) was used for the spliceozyme 
evolution studies.  
The spliceozyme expression level mediated by promoter 5 was characterized using RT-
qPCR (Figure 5). The promoter trc2 (used in previous evolution experiments [25] [26] [22]) 
resulted in an average of 8.3 fewer qPCR cycles than promoter A87.2.5 ("promoter 5"), 
corresponding to >300-fold lower [39] spliceozyme concentration with promoter 5 (A87.2.5) 
than with promoter trc2. Because the trc promoter resulted in about 10,000 ribozyme copies per 
cell [25] the expression level from promoter 5 corresponds to ~30 spliceozyme molecules per 
cell. We were satisfied with this low expression level and the resulting selection pressure for the 
evolution of spliceozymes in E. coli cells described here. Evolutionary adaptation for better use 
of the spliceozymes at low expression levels might be achieved by reduced side product 
formation [26] or - even more exciting - in multi turnover splicing. Multi turnover splicing 
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should be possible for spliceozymes because in contrast to almost all previously developed trans-
splicing group I intron ribozymes the spliceozymes do not get modified during intron removal. 
 
To evolve spliceozymes with broader sequence generality the spliceozyme was challenged 
with different substrate sequences in successive rounds of the evolution (Table 1). In rounds 1-6 
of the evolution, the 100-nucleotide intron sequence, which is removed by the spliceozyme, was 
changed twice (from rounds 2-3 and from rounds 4-5). Additionally, in evolution rounds 7-9, 
both the splice site and the intron sequence were changed. 
 
 
 
 
Figure 5. RT-qPCR analysis of the spliceozyme expression levels for different promoters. The number of 
qPCR cycles to cross a threshold of product concentration is plotted as a function of the dilution of the 
sample. Five different dilutions were used for each sample to reduce the impct of qPCR artifacts. The two 
promoters trc2 and the promoter A87.1 were shifted by an average of 8.3 qPCR cycles relative to the 
promoters in round A87.2. This correponds to >300-fold lower spliceozyme concentration with promoter 5 
(A87.2.5) than with promoter trc2. 
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The evolution experiment started from the single clone W11 which was the winner of the 
previous spliceozyme evolution experiment [26]. In evolution rounds 1-6 (but not 7-9), 10 cycles 
of mutagenic PCR [39] were used to introduce mutations into the spliceozyme (Table 1). In our 
experience, this generated about 2.4 mutations per ribozyme, which were reduced to about 1.1 
mutations per ribozyme after the selection step [25]. Rounds 7-9 relied on the lower mutagenesis 
rate inherent to the used Taq DNA polymerase, which in our hands generated about 4-fold less 
mutations than mutagenic PCR. To adopt the evolving spliceozyme population to different intron 
sequences, these sequences were switched after round 2 from the previously used intron SiC10 
[26] to the second-best intron SiC9, and after round 4 to the third-best intron SiC4 of a previous 
study [22]. 
	
	
	
	
Table 1. Parameters during the 9 rounds of evolving spliceozymes in bacterial cells. The splice cite was 
switched from 258 to 338 after round 6. The intron was switched every two rounds until round 6, then 
every round. The colonies were estimated for every round, both on the selection plates with 
choloramphenicol (LBcam) as well as on plates that only selected for the presence of the plasmid 
(LBamp) Considering the insert ratio (the ration of colonies whose plasmids contain an insert, based on 
18 arbitrary clones) the maximal effective complexity was calculated. The ration between the cell growth 
on LBcam and LBamp is a measure of how well the pools survived the selection pressure. The parameters 
that were not determined are labelled ND.  
 
Round 1 2 3 4 5 6 7 8 9 
Splice Site 258 258 258 258 258 258 448 258 448 
Intron SiC10 SiC10 SiC9 SiC9 SiC4 SiC4 3C39 SiC8 4C6 
Added [Mg2+] 10 10 10 10 10 0 0 0 0 
[cam] ug/mL 4 4 4 4 4 4 4 8 12 
Cfu(LBamp) 3.4E6 4.1E6 3.1E6 2.3E6 1.3E6 4.3E6 6.3E6 5.3E4 1.0E6 
Insert ratio 0.94 0.89 0.89 0.94 0.94 1.00 0.89 0.94 0.94 
Effective cfu 2.8E6 3.6E6 2.8E6 2.2E6 1.2E6 4.3E6 5.6E6 4.9E4 9.9E5 
Plated LBcam 2.8E6 1.8E6 1.9E6 1.2E6 2.6E6 3.6E6 3.3E6 3.3E6 3.8E6 
Effect. Compl. 1.9E6 1.4E6 1.4E6 0.9E6 1.1E6 2.4E6 3.3E6 4.9E4 6.1E5 
Fract. Survive 0.55 0.49 0.40 0.38 0.35 0.17 ND ND ND 
OD600 LBamp 46 28 43 40 51 55 ND ND ND 
OD600 LBcam 11 6.5 6.0 4.0 9.5 3.6 ND ND ND 
LBcam/LBamp 0.24 0.23 0.14 0.10 0.19 0.07 ND ND ND 
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We chose splice site 448 as target site in round 7 to adopt the evolving spliceozyme 
population to a new different splice site, and therefore new flanking sequences. Splice site 448 is 
the second-best splice site in CAT mRNA, less efficient than the best splice site 258 [37]. Splice 
site 448 had never been used for the spliceozymes, therefore it was necessary to identify 
sequences that could be used as introns in splice site 448: Most intron sequences are removed 
quite inefficiently from the splice site by the spliceozymes, and a functional evolution setup 
would require an intron that can be removed easily, at least for the initial rounds of evolution. To 
do this, a library was constructed by inserting a PCR product with 78 randomized positions into 
splice site 448 of the CAT expression cassette in the library plasmid, using spliceozyme W11. 
The selection setup was identical to the evolution setup described in Figure 3, only that the 
introns in the CAT gene provided the genetic diversity and were re-inserted into the plasmid 
library as opposed to the spliceozymes, and that no mutagenic PCR was used. In the first round 
of this selection experiment, the effective complexity at the selection step was 5.4 x 1011 
different intron sequences of the plated bacterial library. Over four rounds of the selection 
procedure the most efficient intron sequences were enriched in the population.  
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Sequencing of 19 clones from rounds 3 and 4 resulted in 5 duplicates, and a total of 13 
different intron sequences that were the correct length. The sequences of these 13 clones were 
compared showing there was a preference for certain nucleotides in 12 different positions of the 
randomized region (Figure 6A). At least 9 out of 13 sequences had a GC at positons N77 and N8 
respectively which is complementary to the spliceozyme sequence they would bind to at these 
positions. These 13 clones were compared for their effect on bacterial growth on medium 
containing four different concentrations of chloramphenicol as well as their sequences (Figure 
6B and C). Four clones showed the best growth, containing the introns 3C8, 3C29, 4C2, and 
4C6.  Intron 3C8 had possible contamination and could not be used for the evolution as a 
precaution. Intron 3C29 was used for evolution round 7 of the spliceozyme evolution, and intron 
Figure 6. Determination of most efficient intron sequence at splice site 448. Sequencing analysis and semi-
quantitative characterization of growth on medium containing chloramphenicol, mediated by plasmids 
containing the W11 spliceozyme and a CAT expression cassette with an intron library inserted after position 
448. (A) A sequence analysis on 19 clones out of which 13 clones were unique sequences. Nucleotides in the 
randomized region (N78) of the intron that occurred in more than 50% of the sequences are shown. The 
numbers show how many sequences had each nucleotide in those specific positions. The bases that appeared 
in more than 50% of sequences are bolded at  their corresponding position. (B) 19 clones from the bacterial 
library were plated at the same density in 5 µL aliquots on four different concentrations of chloramphenicol. 
The plates were grown for 19 hours at 37°C. The 6µg/mL LBcam plate shown has19 clones plated. The 
growth was described by visually assigning numbers between 0 and 100, by two different persons, in 
triplicate. (C) The average of these values was plotted as a function of the chloramphenicol concentration.
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4C2 was used for evolution round 9, both with splice site 448. In evolution round 8, splice site 
258 was used with intron SiC8 [22]. The reason behind this switching of splice sites and introns 
over the course of the evolution was to generate, and enrich for spliceozymes that showed less 
dependence on the substrate sequence. 
Over the course of the evolution, the effective complexity of the evolving population had an 
upper limit of at least 49 thousand (Table 1). For rounds 1-6 the upper limit was 0.9 million. The 
fraction of surviving clones decreased from 24% in round 1 to 7% in round 6. This would signal 
a decrease in fitness of the evolving pool, and can be the result of a high mutational load [25] 
[40]. Nevertheless, the evolving pool also survived the additional evolution rounds 7-9, where it 
was challenged to switch splice sites and intron sequences. In Rounds 8 and 9 the effective 
complexity was lowered due to choosing LB-agar plate with higher chloramphenicol 
concentrations, 8 and 12 µg/mL respectively, as well as switching splice site every round. 
After a total of nine rounds of evolution, the selected spliceozyme genes were re-cloned into 
fresh library plasmid, with intron SiC8 in splice site 258. The plasmids were transformed into 
fresh E. coli cells, and a total of 80 bacterial clones were screened for growth on medium 
containing 10 µg/mL chloramphenicol. Eight clones that showed stronger growth than 
spliceozyme W11 were chosen for further analysis. 
The eight 'winners' of the evolution were challenged to splice in two different sequence 
contexts, splice site 258 (with intron SiC8) and splice site 448 (with intron 4C2). These growth 
assays were done in independent triplicate experiments, mostly in two triplicates, resulting in 
three to six data points for each clone (Figure 7). The eight clones showed very diverse behavior, 
with all clones better or on par with the parental spliceozyme W11 on either target sequence. For 
example, clone N3 mediated by far the most efficient growth on splice site 258, while clone C11 
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mediated the most efficient growth on splice site 448. The behavior of most clones was very 
robust between experiments, whereas clone 42 showed dramatic differences between 
experiments, perhaps mediated by metastable folding or annealing characteristics influenced by 
the mutations. 
 
In three cases, it was possible to ascribe the different bacterial growth on medium containing 
chloramphenicol to specific spliceozyme mutations (Figure 8). First, spliceozyme clone N1 
carried only a single mutation compared to W11 (A369G), which resulted in much better growth 
with splice site 258 and SiC8. The growth of clone N1 with splice site 448 is within error of 
W11, suggesting that mutation A369G specifically improves splicing on splice site 258. Second, 
spliceozyme C11 carried mutation A175G, in addition to the same mutation as N1 (A369G). 
Growth of clone C11 is dramatically better with splice site 448, suggesting that mutation A175G 
Figure 7. Growth of bacterial clones containing nine individual spliceozymes in two different sequence 
contexts.  The nine clones analyzed were clone W11, the starting point of the evolution, and eight clones that 
were isolated from round 9 of the evolution experiment. Growth on LBcam plates was measured by growing 
the bacterial cells for 19 hours on an LB plate with a chloramphenicol concentration of 10 µg/mL, 
suspending the cells in LB medium, and measuring the OD600 compared to LB medium. The growth (OD600) 
in the sequence context of splice site 258 is shown on the x-axis, the growth in the sequence context of splice 
site 448 on the y-axis. The data from each clone are shown in colored symbols, with their legend on the right. 
The data points from each clone are encircled to help comparison of all data points.  
Figure 5
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specifically improves splicing on splice site 448. On splice site 258, clone C11 shows a much 
larger variation than N1, suggesting that A175G leads not only to higher efficiency with splice 
site 448 but also to a destabilization of the beneficial effect of A369G with splice site 258. Third, 
clone C17 carried only the single mutation T317A, which caused a significant improvement on 
splice site 258 but no improvement on splice site 448. The T317A mutation also shows up in 
clones C32, N2, and N3 which all perform better on splice site 258 than W11. These three 
mutations are highlighted on the Tetrahymena Group I intron secondary structure (Figure 8A). 
The mutations, highlighted on 3D models of the Tetrahymena Group I intron, are all on the 
outside surface of the ribozyme suggesting possible interactions with outside factors (Figure 8B). 
The model suggests that mutations T317A and A369G may have an effect on the interaction with 
the intron portion close to the 3’ splice site. For the other six clones the mutations were not 
related to other clones by point mutations and therefore did not allow ascribing the growth 
effects to individual mutations; this will require additional analysis (Figure 8C). Together, these 
results showed that spliceozyme mutations have specific improvements of bacterial growth on 
LBcam in the context of different substrate sequences. 
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Figure 8. Mutations that appeared on clones in Round 9 of the evolution. The upstream and downstream
exons (red) and the intron (blue) are depicted in the structures. (A) Mutations A369G (C11 and N1), 
A175G (C11), and T317A (C17) shown on secondary structure of spliceozyme (black). (B) Westhoff
model of Tetrahymena Group I Intron (gray) with mutations highlighted for each clones N1 (A369G), C11 
(A175G and A369G), and C17 (T317A). (C) All mutations that appeared in 8 clones tested in growth 
assays W11, as shown in Figure 7, arranged by growth on SS258 (top table) and SS448 (bottom table). 
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The difference in the effects of the spliceozyme mutations on different substrates could be 
due to (i) the difference between the two splice sites 258 and 448, (ii) due to the introns, or (iii) 
due to a combinatorial effect of splice sites and introns. To discriminate between these 
possibilities, we measured bacterial growth on LBcam with a combination of splice site and 
intron sequence that had been previously used in the evolution, SiC4 for splice site 258 and 3C29 
for splice site 448, for all nine spliceozyme constructs. The results showed that there was no 
clear correlation between the splice sites when using different introns (Figure 9). For splice site 
258, a trend line could be drawn between the growth on both introns, but clone C42 was a clear 
outlier to this trend. The clones generally grew better in both splice site 258 sequence contexts 
compared to the splice site 448 constructs. For splice site 448, two different trend lines could be 
drawn. All clones except W11 performed better on splice site 448 intron 4C2 than intron 3C29. 
The W11 results were very similar for both intron contexts, similar to the intron selection. The 
introns that were chosen from the splice site 448 intron selection may have been the best for 
W11, but not the other clones. More clones would need to be tested in order to see whether there 
is a significant correlation between splice site with different introns. 
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To test whether bacterial factors are necessary for the effects of the spliceozyme mutations 
in bacteria we performed in vitro assays of the spliceozyme variants on the two, respective 
substrate RNAs; the cat substrate with intron SiC8 at splice site 258 and the cat gene with intron 
4C2 at splice site 448. In these assays, the same constructs were used as described previously for 
the in vitro characterization of the spliceozyme mutant W11 [26]. Substrate CAT pre-mRNA 
fragments are internally labelled with 32P, allowing to follow the formation of products and side 
products after denaturing polyacrylamide gel electrophoresis (PAGE) and quantitative analysis 
of autoradiograms.  
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Figure 9. Growth of bacterial clones containing nine individual spliceozymes in two different 
sequence contexts with two different introns for each: Splice Site 258 with either introns Si4 and 
Si8 and Splice Site 448 with introns 3C29 and 4C2. The nine clones analyzed were clone W11, the 
starting point of the evolution, and eight clones that were isolated from round 9 of the evolution 
experiment. Growth on LBcam plates was measured by growing the bacterial cells for 19 hours on 
an LB plate with a chloramphenicol concentration of 10 µg/mL, suspending the cells in LB 
medium, and measuring the OD600 compared to LB medium. (A) The growth (OD600) in the 
sequence context of splice site 258 with intron Si8 is shown on the x-axis, the growth in the 
sequence context of splice site 258 with intron Si4 on the y-axis. The data from each clone are 
shown in colored symbols, with their legend on the right. (B) The growth (OD600) in the sequence 
context of splice site 448 with intron 4C2 is shown on the x-axis, the growth in the sequence 
context of splice site 448 with intron 3C29 on the y-axis. The data from each clone are shown in 
colored symbols, with their legend on the right. The axis differ based on growth activity for each 
splice site and intron.
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The results indicated that for splice site 258, none of the variants performed significantly 
better than W11 even after 60 min (Figure 10).  The effects of N3 as seen in the in vivo growth 
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Rate constants (M-1 min-1)
W11 C23 C42 C17 C32 C11 N1 N2 N3
SS 258 0.010 0.006 0.014 0.005 4.17x 10-6 0.003 0.216* 0.095 0.256*
SS 448 0.014 0.022 0.023 0.029 0.013 0.025 0.016 0.022 0.013
Figure 10. Substrate CAT pre-mRNA fragments are internally labelled with 32P, allowing to follow 
the formation of products and side products after denaturing polyacrylamide gel electrophoresis 
(PAGE) and quantitative analysis of autoradiograms. (A) Time course of 8 spliceozymes clones 
and W11 reacting with CAT pre-mRNA at splice site 258. Samples were taken at 7,20, and 60 min. 
(B) Time course of 8 spliceozymes clones and W11 reacting with CAT pre-mRNA at splice site 
448. Samples were taken at 15, 30, 60, and 120 min. (C) Plot of % product calculated from 
autoradiograms and against time in minutes for all 8 clones and W11 for splice site 258 gels. 
Markers are actual time points whereas lines are models based on calculated rates. (D) Plot of % 
product calculated from autoradiograms and against time (min) for all 8 clones and W11 for splice 
site 258 gels. Markers are actual time points values whereas lines are models based on calculated 
rates. (E) Rates calculated using a second order rate equation. Slower rates are shown in table. 
Values with “*”used a first order rate equation. 
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assays were not seen in the in vitro results Six variants and W11 used a second order reaction 
rate in order to describe the time course data. A first order reaction rate could only be applied to 
variants N1 and N3. Of those second order reaction rates, C42 was the fastest at 0.014, followed 
by W11 at 0.010, N2 at 0.095, C23 at 0.006, C17 at 0.005, C11 at 0.003, and C32 at 4.17 x 10-6 
M-1min-1. For splice site 448, all the variants performed slightly better than W11 at 15, 30, 60 
and 120 minutes. The effects of C11 as seen in the in vivo growth assays were not seen in the in 
vitro results. A second order rate reaction could be applied to the time points. Variant C17 had 
the fastest rate at 0.029, C11 at 0.025, C42 at 0.023, C23 and N2 at 0.022, N1 at 0.016, W11 at 
0.014, and N3 and C32 at 0.013 M-1min-1.  
 
The in vitro assays with the spliceozyme RNA and CAT pre-mRNA and the in vivo growth 
assays showed no significant correlation. There are two possible interpretations of these results: 
Either bacterial factors are utilized by the spliceozymes, or the truncations of the substrate 
sequences to ~800 nucleotides prevented the replication of the mutation effects in vitro. This 
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Figure 11. Correlation between in vitro % product and bacterial growth between same introns. 
(A) Data from bacterial growth assays plotted against data from % product quantified from 
autoradiograms of in vitro assays using intron SiC8 at splice site 258. (B) Data from bacterial 
growth assays plotted against data from % product quantified from autoradiograms of in vitro 
assays using intron 4C2 at splice site 448. 
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question needs to be addressed in follow-up work, perhaps with the technically difficult use of 
the full-length CAT pre-mRNA of 1,070 nucleotides instead of the CAT pre-mRNA fragment.  
Together, this study showed, based on an evolution experiment of spliceozymes in bacterial 
cells, that specific spliceozyme mutations are able to improve spliceozyme efficiency in bacterial 
cells and improve performance in difference substrate sequence contexts. This suggests that 
spliceozymes could be generated with improved efficiency on a wide range of substrate 
sequences with further analysis and experiments. It is currently unclear whether the evolved 
spliceozyme mutations require bacterial factors to exhibit their effects.  
I would like to acknowledge Logan Norrell on his work in the results and materials and 
methods sections- the identification of promoter 5 and the first six rounds of the spliceozyme 
evolution. The results section was initially written by Ulrich Muller, including figures 2-5 and 
Table 1.  
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Discussion 
 
This study showed, based on an evolution of spliceozymes in bacterial cells using lower 
expression levels and multiple splice sites, that specific spliceozyme mutations are able to 
improve spliceozyme efficiency in bacterial cells. Importantly, some mutations, and sets of 
mutations, improved the performance in several different substrate sequence contexts. This 
suggests that further analysis, and perhaps further evolutions, could generate spliceozymes with 
improved efficiency on a specific splice site or broad range of substrate sequences.  
Evolutions could be done to generate spliceozymes which perform efficiently on an 
individual splice sites as was done for splice site 258 to generate W11 [26]. The spliceozyme 
went through 10 rounds of evolution to produce clone W11. In this study, an additional 6 rounds 
were completed with lower expression levels using clone W11 as a starting point. All 8 clones 
from Round 9 that were tested performed better than W11 in bacterial cells. If the selection 
pressure had been increased by lowering expression levels as well as increasing the 
chloramphenicol concentration during these 6 rounds, a more efficient clone may have been 
generated. The lower expression level alone was not enough selection pressure to produce a 
clone that was significantly more efficient. Similarly, in order to find a spliceozyme better suited 
for splice site 448, an evolution could be performed specifically for that splice site. Introns could 
be changed every two rounds to prevent intron sequence specificity and selection pressure could 
be increased the last three to four rounds of the evolution to generate a spliceozyme efficient for 
splice site 448.  
		 27 
In order to generate a clone that may be more general for different splice sites, W11 could 
be a starting point but splice sites could be changed more frequently earlier on in the evolution. 
Two rounds with promoter 5 for lower expression level could be done to make sure the 
spliceozyme mediates growth. Then, the splice site could be switched to 448 so that the clones 
do not become accustomed to splice site 258. The next best splice site, 405, could be added into 
the evolution as well [37]. Every two to three rounds the intron and splice site could be switched 
and the chloramphenicol concentration could be gradually increased to escalate the selection 
pressure. This way the spliceozyme does not get accustomed to a specific splice site or intron but 
has enough opportunity to gradually gain mutations that will increase efficiency across all three 
splice sites and introns. Overall the number of rounds needs to be increased and the splice sites 
need to be changed frequently.  
In this study, mutations improved the performance of clones in bacterial cells but did not 
exhibit the same behavior in vitro (Figure 11). Clone C11, with mutations A369G and A175G, 
showed improvement on splice site 448 compared to W11 in bacterial cells but did not show a 
significant improvement in the in vitro assays. The growth of clone N1 (only has A369G 
mutation) with splice site 448 is within error of W11, suggesting that mutation A369G does not 
improve splicing with splice site 448. Mutation A175G can be examined more closely to 
determine its effect. An A175G mutation could be made using site directed mutagenesis on W11, 
and the growth on LBcam plates could be compared with clone C11 and clone W11. If this 
mutation causes more growth than W11 and similar growth to C11 on splice site 448, this would 
suggest that cellular factors may be an influence in the mutation effects. Both mutations on clone 
C11 are on the external portions of the Tetrahymena group I intron tertiary structure which could 
suggest interactions with cellular factors (Figure 8B). A protein pull down experiment and 
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further studies could be performed to determine which cellular factors are necessary and their 
effects.  
It is currently unclear whether the evolved spliceozyme mutations require bacterial factors to 
exhibit their effects. The answer to this question will decide whether spliceozymes could be 
evolved in E. coli cells, or require the technically more difficult evolution in human cell lines for 
possible clinical applications. Nevertheless, the improved spliceozyme efficiency after evolution 
in bacterial cells suggests that it is only a technical question whether spliceozymes could be 
generated that are efficient enough for clinical applications. 
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Materials and Methods 
 
Construction of spliceozyme/CAT pre-mRNA plasmids  
The plasmid containing the spliceozyme gene and the CAT gene was based on previously 
described pUC19-based expression system, which includes a multiple cloning site with SacI, 
BamHI, SphI, and HindIII. The ribozyme gene was inserted between restriction sites SacI and 
BamHI and the CAT gene was inserted between SphI and HindIII as described in [22]. To 
prepare for the insertion of introns at position 448, a restriction enzyme site was introduced using 
a T423 mutation to create a PciI restriction site through PCR mutagenesis. Another PciI site in 
the origin gene was silently mutated through PCR mutagenesis so only one unique PciI site 
would remain in the plasmid.  
 
Selection of Weak Promoter Sequences that still mediate growth  
Five different promoter sequences derived from LacI operator, termed single-input gates 
(SIGs), were reported in [37]. These promoters were identified as B4, A81, A38, A87, and A52 
with regulatory ranges given as 2.5 x 104, 1.5 x 104, 3.6 x 103, 2.6 x 102, and 6.2 x 102, 
respectively. W11 spliceozymes were PCR amplified with primers adding one of the five LacI 
promoters at the 5' end into pUC19b carrying a chloramphenicol gene with intron SiC10 at splice 
site 258. 
After verification of the correct promoter sequences, growth curves for each LacI-derived 
promoter were performed in triplicate. An overnight culture of 5 mL LB with 100 µg/mL 
ampicillin was inoculated with a single colony and the next morning 5 µL of 1 M IPTG was 
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added to activate the LacI-derived promoters and downstream W11 spliceozymes for 1 h at 37°C 
with shaking. This induced starter culture was used to inoculate a 20 mL LB culture with 4 
µg/mL chloramphenicol and 1 mM IPTG to a starting OD600 of 0.05 ± 0.01.  
Further reduction of expression of the LacI A87 promoter was accomplished in four 
steps. First, four nucleotide randomized libraries flanking the 5'-end of the -35 box, the 3'-end of 
the -35 box, and the 5'-end of the -10 box were constructed using the following 5' primers and 
the 3' primer in purple for PCR. Four 5' primers were used including 5' GCTGCCTTTCGTCTT-
CAATANNNNTTGACAATCAATGTGGATTTCTGATCTGTGTGTCTG, 5'GCTGCCTTTC-
GTCTTCAATAATTCTTGACANNNNATGTGGATTTTCTGATACTGTGTGGCT, 5' GCT-
GCCTTTCGTCTTCAATAATTCTTGACAATCAATGTGGATTNNNNGATACTGTGTGGCT
G, 5' ACTGGGATCCGTACAACGTCGTCTTAGCTGCCTTTCGTCTTCAATA. The 3' primer 
used for PCR was 5' CGGAGCTCCAAAAAACCCTCAAGACCCGTTTAGAGGCCCCAAG-
GGGTTATG. These N4 libraries were analyzed by the same growth assay method and A87 3.1a 
was shown to have the slowest rate of growth.  
Second, to assist cloning during the in vivo evolution, a KpnI site was added to A87 3.1 
to produce A87.1. Third, another N4 randomized library, A87.2 library, was constructed, this 
time within most nucleotides of the 5'-10 box. The weakest promoters were first selected by a 
growth assay in LB containing 4 µg/mL chloramphenicol and 1 mM IPTG.  Fourth, Candidate 
clones were analyzed by RT-qPCR to determine levels of spliceozyme expression. To quantify 
the amount of spliceozymes being produced per cell, total RNA was isolated from 
logarithmically growing E. coli cells after induction with 1 mM IPTG, using the RNeasy kit 
(Qiagen). Two hundred nanograms of total RNA was reverse-transcribed using SuperScript III 
RT (Invitrogen) and a short oligonucleotide complementary to the 3’-end of the spliceozyme. 
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One-tenth of the reverse transcription reaction was used as template for the quantitative PCR. 
The PCR was performed using two sets of primers with the SYBR green master mix (Thermo-
Fisher) on a Fast 7500 RT-PCR machine (Applied biosystems). The method started with a 10-
min incubation at 95 °C. Each PCR cycle included incubations of 30 sec at 95°C, 30 sec at 57°C, 
and 30 sec at 72°C. Each PCR cycle included incubations of 30 sec numbers from three eightfold 
serially diluted samples confirmed the linearity of the assay.  
 
Selection of efficient intron sequences for Splice Site 448 
Plasmid libraries containing partially randomized introns were transformed into 
electrocompetent E. coli cells, which were plated on LB-agar containing 100 mg/mL ampicillin. 
The plates were washed with LB medium, after incubation at 37°C for 19 hours, and the bacterial 
libraries were frozen as glycerol cell stocks. The bacterial libraries were then diluted to 
approximately 3,000,000 cfu/mL with LB medium and induced with 1mM IPTG by shaking for 
1 hour at 37°C. 100µL of this culture were plated onto each of 20 LB-agar plates containing 
4µg/mL chloramphenicol, and allowed to grow for 17 hours at 37°C for the selective step. The 
plates were then washed with LB medium to create glycerol cell stocks. The intron sequences 
were isolated, amplified, and ligated back into fresh plasmids to create a library for the next 
round. These steps were completed again 4 times for a total of 4 rounds of selection.  
Individual colonies from Rounds 3 and 4 were selected and analyzed for the sequences 
and efficiencies of individual introns. Each clone was transformed into electrocompetent E. coli 
cells, and plated on LB-agar containing 100 mg/mL ampicillin. After incubation at 37°C for 16 
hours, the plates were washed with LB medium to generate a cell stock of each clone. Each clone 
was diluted to 2000 cfu/5µL. After inducing each dilution with 1mM IPTG by shaking at 37°C, 
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5µL of each clone was plated on a series dilution of LB-agar plates with either 2, 4, 6, or 8 
µg/mL chloramphenicol and allowed to grow for 19 hours at 37°C. Each clone’s growth was 
independently visually analyzed by two people and given a rating, 0 (no growth) to 100 (most 
growth across all plates). Both the plating and the analysis were done in triplicate. The ratings 
were plotted against chloramphenicol concentration in order to determine the efficiency of the 
introns. Quantitative measurements were taken by pipetting 10µl of fresh LB up and down on the 
5µL growth spots and measuring the OD600. This was not only laborious and time consuming but 
also inaccurate due to artifacts from the LB agar being added to rather than just the colonies 
themselves.  
 
Spliceozyme Evolution 
Rounds 1-6:  
The evolution was completed essentially as described [24]. Briefly, spliceozyme constructs were 
randomized by mutagenic PCR and cloned into library plasmid. Library plasmids containing 
spliceozyme sequences were transformed into E. coli cells, plated on LB agar medium 
containing 100 μg/mL ampicillin (amp) and incubated at 37°C for 16 h to create pools. LB agar 
plates containing pools of E. coli cells were washed using liquid LB medium. The resulting 
medium was diluted to an OD600 of 0.0015 or 300,000 cfu/mL, induced with IPTG to a final 
concentration of 1 mM and shaken at 37°C for 1 h. E. coli cells were then plated on LB agar 
medium containing the indicated concentration of chloramphenicol (Table 1) and incubated at 
37°C for 16 h to select for spliceozyme constructs able to mediate antibiotic resistance. LB agar 
plates were washed using liquid LB medium and plasmids were isolated by miniprep. Five or 10 
clones were chosen for sequencing from each round of evolution.  
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Rounds 7-10: 
The plasmid 448-3C29, 258-SiC4, and 448-4C6 were prepared for rounds 7,8, and 9 
respectively. 5µg of each plasmid was digested at the KpnI and SacI sites and 
dephosphorylated.1nM of the R6 spliceozyme pool was amplified with 5' CAATGTGGTACCA-
CAAAGCCTGTGTGGCTGGGGATAAAAGTTATTAGGC for Splice site 448 or 5' CAATGT-
GGTACCACAAAGCCTGTGTGGCTGTCCCAAAAAGTTATTAGGC for splice site 258 and 
3' primer GCCAGTGAATTCGAGCTC for 25 cycles. The pool was digested using KpnI and 
SacI at 30°C and the spliceozyme was ligated to the plasmid used for each round. The plasmid 
with spliceozyme insert was transformed into commercially available electrocompetant cells and 
plated LB-Agar plates containing 100 mg/mL ampicillin. After growing overnight, each plate 
was washed with 2mL of LB. An equal volume of glycerol was added to create a cell stock. The 
OD600 of the cell stocks were measured and then one cell stock was diluted to 3,000,000 cfu/mL. 
The dilutions were incubated at 37°C with a final concentration of 1mM IPTG for 1 hour with 
shaking. 100 µL was plated onto each LB-Agar plate containing 4 µg/mL chloramphenicol for 
Round 7. After growing for 20 hours. Each plate was washed with 3 mL of LB and centrifuged 
for 5 min at 5000g. The supernatant was removed and 5mL of fresh LB was added. This plasmid 
pool was miniprepped and named the R7 plasmid pool. For cycles 8 and 9, 1nM of the R7 and 
R8 pools respectively were amplified with the same primers described for 25 cycles. The 
products were run on a 1% agarose gel the correct sized band (536nt) was cut out to avoid any 
contaminating DNA. The gel piece was added to 200 µL of water and heated at 90°C for 5 min 
to melt the gel. 1µL of the melted gel was used for another 25 cycles of 100 µL PCR reaction 
with the same primers. The amplified spliceozyme was ligated to the respective cut and 
dephosphorylated plasmid for each round, transformed into electrocompetant cells, plated on 
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LBagar with 100 mg/mL ampicillin and made intro glycerol stocks. The stocks were then diluted 
to 3,000,000 cfu/mL and incubated with a final concentration of 1mM IPTG at 37°C for 1 hour 
with shaking to mediate antibiotic resistance. 100 µL were plated onto 5 plates of LB agar with 
either 4, 8, 12, 20, or 40 µg/mL chloramphenicol. After waiting 19 hours, the plates were 
compared and LB-agar plates with 8 µg/mL chloramphenicol were chosen to be washed four 
Round 8 and the 12 µg/mL for Round 9. These plates did not have a lawn of E. coli but mediated 
enough growth that there were around 1000’s cfu/plate. Each plate was washed with 3 mL of LB 
and centrifuged for 5 min at 5000g. The supernatant was removed and 5mL of fresh LB was 
added. This plasmid pool was miniprepped. 
Notes: Contamination was seen during this evolution and therefore steps were added to 
complete Rounds 8 and 9 of the evolution. The plasmids from the previous round were still 
appearing so that we had different sets of introns in our pool. This could be due to (1) 
contamination on the spreaders (2) Complete plasmid being replicated during PCR. To avoid 
contaminants from the spreaders: the spreaders were placed in bleach for a minimum of 15 
minutes, washed with water, placed in a flame, and then left to cool before use. To avoid 
contamination from PCR, a step was added into the evolution cycle. Instead of 1 PCR step, the 
product was run through a 1% agarose gel, the correct sized band was excised, PCR was 
performed with this product and the evolution was continued. This step ensures that only the 
spliceozyme fragment was amplified. 
 
Growth measurements in E. coli 
Spliceozyme constructs were inserted into library plasmids: 258-SiC4, 258-SiC8, 448-
3C29, and 448-4C2. Library plasmids containing spliceozyme sequences were transformed into 
		 35 
E. coli cells, plated on LB agar medium containing 100 μg/mL ampicillin (amp) and incubated at 
37°C for 16 hours. A clone was selected off the plate and grown in a liquid culture 
containing100 µg/mL amp overnight. The OD600 of the overnight culture was measured and the 
culture was diluted to 50,000 cfu/mL and incubated with a final concentration of 1mM IPTG at 
37°C for 1 hour with shaking to mediate antibiotic resistance. 100 µL was plated on a LB agar 
plate with 10 µg/mL chloramphenicol and grown for 19 hours at 37°C. The plates were then 
washed with 2mL of fresh LB and the OD600 was measured. This was done in independent 
triplicated experiments.  
 
Spliceozymes and pre-mRNAs for in vitro work 
The Spliceozymes and the CAT pre-mRNA substrate were made by in vitro transcription 
from PCR products with T7 RNA polymerase, as described in [37]. The PCR of the 
spliceozymes used the 5' primer AATTTAATACGACTCACTATTAAGTCCCAAAAAGTTA-
TTAGG for splice site 258 and AATTTAATACGACTCACTATTAAGGGGATAAAAGTTA-
TTAGG for splice site 448 (the T7 promoter is underlined and T7 enhancer is in bold). The PCR 
of the spliceozyme used the 3' primer TATGCGATTAGTTCCAGCGGC but clones that had a 
A369G mutation used the 3' primer TATGCGATTAGCTCCAGCGGC. PCR amplification of 
the template for T7 transcription of CAT pre- mRNA, the 5' primer AATTTAATACGACTCA-
CTATAGGGAGGAGCTAAGGAAGCTAAAATG and the 3' primer CGCCCCGCCCTGCCA-
CTCATC were used (the T7 promoter is underlined and T7 enhancer is in bold). Transcriptions 
were performed at 37°C for 3 hours in 40 mM Tris/HCl pH 7.9, 26 mM MgCl2, 5 mM DTT, 
0.01% Triton X-100, 2.5 mM spermidine and 2.5 mM of each NTP. The CAT pre-mRNA 
substrates were internally labelled using additional [32P]-ATP and a decreased concentration of 
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1mM ATP. Transcribed spliceozymes and substrate CAT pre-mRNAs were purified by 7 M urea 
5% polyacrylamide gel electrophoresis (PAGE), eluted in 300 mM NaCl, ethanol precipitated, 
re-dissolved in water. RNA concentrations were measured using the A260.   
 
In vitro reactions  
In vitro reactions were done essentially as described in [22]. The final spliceozyme 
concentration was 300 nM and CAT pre-mRNA substrate concentrations were 100 nM. 
Reactions were incubated in 5 mM MgCl2, 135 mM KCl, 50 mM MOPS/NaOH pH 7.0, 20 mM 
GTP, and 2 mM spermidine, at 37°C, in reaction volumes of 20 µL. Spliceozyme and substrate 
were pre-incubated separately in the reaction buffer for 10 minutes at 37°C before combining the 
solutions to start the reaction. Samples were taken in 2 µL aliquots after reaction times of 7, 20, 
and 60 minutes for spliceozymes being tested with Splice Site 258 and 15,30,60, and 120 
minutes for clones being tested with Splice Site 448. In vitro reaction products were separated on 
7 M urea 5% PAGE and visualized by phosphor-imaging. Bands were quantified on a 
phosphorimager (PMI, Bio-Rad) using the Bio Rad software Image Lab.  
 
I would like to acknowledge Logan Norrell on his work in the materials and methods sections- 
the identification of promoter 5 and the first six rounds of the spliceozyme evolution. 
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